| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA1193: Ibrutinib with R-CHOP for untreated mantle cell lymphoma when a stem cell transplant is suitable |
|
Medicine details |
|
| Medicine name | ibrutinib (Imbruvica®) |
| Formulation | 560 mg Buccal tablet |
| Reference number | 7300 |
| Indication | In combination with rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone (R-CHOP) for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are eligible for autologous stem cell transplantation (ASCT) |
| Company | Janssen-Cilag Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 26/08/2026 |
| NICE guidance | |